⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18998995 | 1.00 | — | — | |
| SCHEMBL16801609 | 1.00 | — | — | |
| SCHEMBL16716623 | 1.00 | — | — | |
| SCHEMBL18998992 | 1.00 | — | — | |
| SCHEMBL10429762 | 0.84 | — | — | |
| SCHEMBL15870583 | 0.84 | — | — | |
| SCHEMBL10429913 | 0.84 | — | — | |
| SCHEMBL10429761 | 0.84 | — | — | |
| SCHEMBL23155698 | 0.79 | — | — | |
| SCHEMBL22880656 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023192375-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2022109182-A9 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022109182-A1 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2020081508-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-04-23 | — | — | WO | disclosed |